In a second recent trial, the improvement in cognition after 6months of rosiglitazone treatment was significant only in AD patients who didnot have the ε4 allele of the apolipoprotein E [92], a genotype associate with a higher risk todevelop AD. This evidence concerns the gene APOE and Alzheimer disease.